Masimo (MASI) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
18 Mar, 2026Executive summary
Masimo entered into a definitive agreement to be acquired by Danaher Corporation for $180.00 per share in cash, representing a 38% premium to the pre-announcement trading price.
The merger will result in Masimo becoming a wholly owned subsidiary of Danaher, with its shares delisted from Nasdaq and deregistered under the Exchange Act.
The transaction is subject to approval by Masimo stockholders, regulatory clearances, and other customary closing conditions, with expected completion in the second half of 2026.
A special meeting of stockholders will be held virtually to vote on the merger and a non-binding advisory vote on executive compensation related to the merger.
Voting matters and shareholder proposals
Stockholders will vote on the adoption of the Merger Agreement and a non-binding advisory vote on compensation for named executive officers in connection with the merger.
Approval of the merger requires a majority of outstanding shares; abstentions and broker non-votes count as votes against.
Politan Capital Management LP, holding approximately 8.8% of voting power, has entered into a Voting Agreement to support the merger.
The board unanimously recommends voting FOR both proposals.
Board of directors and corporate governance
The board unanimously approved the merger, determined it is fair and in the best interests of stockholders, and recommends approval.
The board considered strategic alternatives, prior sale processes, and engaged financial and legal advisors throughout negotiations.
The board negotiated an increase in the offer price from $166 to $180 per share.
Latest events from Masimo
- $1B credit facility signed in Dec 2025 with leverage and coverage covenants, maturing 2030.MASI
Q4 202527 Feb 2026 - Masimo to be acquired by Danaher for $180 per share, pending shareholder approval.MASI
Proxy Filing17 Feb 2026 - Board approves $180/share Danaher acquisition; shareholder vote and regulatory review pending.MASI
Proxy Filing17 Feb 2026 - Shareholders will vote on a $180/share all-cash merger, with closing expected in late 2026.MASI
Proxy Filing17 Feb 2026 - Q2 revenue up 9% to $496.3M, driven by healthcare growth; non-GAAP EPS $0.86, guidance raised.MASI
Q2 20242 Feb 2026 - Stabilized growth, innovation, and a potential JV or spin-off set the stage for margin expansion.MASI
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026 - Accelerated consumer separation and margin expansion drive renewed healthcare growth focus.MASI
Jefferies 2024 Global Healthcare Conference1 Feb 2026 - Healthcare growth and margin expansion continue, with strategic options for consumer audio ongoing.MASI
2024 Wells Fargo Healthcare Conference22 Jan 2026 - Q3 revenue up 5.4% to $504.6M, with healthcare growth and raised EPS guidance for 2024.MASI
Q3 202416 Jan 2026